PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 lowers HIF-1α protein levels and HIF-1 transactivation in hypoxia and in normoxia in a variety of cancer cell lines, but has a more pronounced effect on translation of proteins, such as HIF-1α in hypoxia. PX-478 also enhances the radiosensitivity of prostate carcinoma PC3 cells. PX-478 causes reduced fibrosis and fewer inflammatory infiltrates in high-fat-diet mice adipose tissues.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 70 mg/mL
Water 70 mg/mL
|Source||Oncotarget (2017). Figure 1. PX-478|
|Cell Lines||MiaPaCa2 cells|
|Concentrations||10, 20, 50, 100, and 200 μM|
|Results||When MiaPaCa2 cells were exposed to the highest concentration of PX-478 and noscapine, HIF-1 expression levels equaled to 55% and 62% of the control value, respectively.|
Selective inhibition of hypoxia-inducible factor 1α ameliorates adipose tissue dysfunction.
Sun K, et al. Mol Cell Biol. 2013 Mar;33(5):904-17. PMID: 23249949.
PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells.
Palayoor ST, et al. Int J Cancer. 2008 Nov 15;123(10):2430-7. PMID: 18729192.
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha.
Koh MY, et al. Mol Cancer Ther. 2008 Jan;7(1):90-100. PMID: 18202012.
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.
Welsh S, et al. Mol Cancer Ther. 2004 Mar;3(3):233-44. PMID: 15026543.
|Related HIF Products|
Daprodustat (GSK1278863) is a novel, orally active HIF-prolyl hydroxylase inhibitor.
|Molidustat (BAY 85-3934)
Molidustat (BAY 85-3934) is a potent hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor with IC50 of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD, respectively. Phase 2.
MK-8617 is an orally active pan-inhibitor of Hypoxia-inducible factor prolyl hydroxylase 1−3 (HIF PHD1−3), inhibiting PHD1, 2, 3 with IC50s of 1.0, 1.0 and 14 nM, respectively.
BAY 87-2243 is a potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor.
Chlorogenic Acid is an analog of caffeic acid that displays antioxidant, analgesic, antipyretic and chemopreventive activity.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.